Gemini Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced the grant of an inducement award to Brian Piekos, Gemini’s Chief Financial Officer and the grant of an inducement award to Dr. Sam Barone, Gemini’s Chief Medical Officer. In accordance with NASDAQ Listing Rule 5635(c)(4), the award was approved by Gemini’s Compensation Committee and made as a material inducement to both Mr. Piekos’ and Dr. Barone’s entry into employment with the Company.